{"slug":"pt-141-selank-ssri","verification":{"valid":true,"entries":17,"head":"b995ed4fc3b5f9876fe0daea27f285aa1d4f77d5d69903ff447ff92278900afb"},"energy":{"passes":17,"tokens_in":3195,"tokens_out":323,"tokens_total":3518,"cost_usd":0,"models":{"grok/grok-4.3":1,"grok-4.3":2,"system/audit-repair":9,"kimi/moonshot-v1-8k":1,"repair":1,"fill-slots":2,"owner":1},"head":"b995ed4fc3b5f9876fe0daea27f285aa1d4f77d5d69903ff447ff92278900afb"},"provenance":[{"ts":"2026-06-29T09:23:11.459Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: PT-141 + Selank for SSRI Users\n\nAudience: 37M. The problem: SSRIs cause sexual dysfunction and breakthrough anxiety. Why the stack maps: PT-141 restores arousal; Selank reduces anxiety without sedation/addiction. Novelty: 9/10.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"pt-141-selank-for-ssri-users\",\n  \"title\": \"PT-141 + Selank for SSRI Users: Evidence Review\",\n  \"body\": \"## PT-141 (Bremelanotide) Evidence\\n\\nPT-141 is a melanocortin receptor agonist approved by the FDA in 2019 as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Phase 3 randomized controlled trials demonstrated statistically significant improvements in sexual desire scores and reductions in related distress compared to placebo.\\n\\nHuman trial data exist for sexual function in both women and men, including some with erectile dysfunction unresponsive to PDE5 inhibitors, but no published human trials specifically examine PT-141 in SSRI users.\\n\\n## Selank Evidence\\n\\nSelank is a synthetic heptapeptide with reported anxiolytic effects in Russian clinical studies. A 2008 randomized comparison in 62 patients with generalized anxiety disorder and neurasthenia found efficacy comparable to medazepam on Hamilton Anxiety Rating Scale and other measures, without sedation, cognitive impairment, or withdrawal.\\n\\nAdditional Russian trials (e.g., 30–70 patients) reported similar anxiolytic benefits and cognitive enhancement versus benzodiazepines. Selank is approved in Russia for anxiety disorders. No large-scale Western RCTs or data specific to SSRI breakthrough anxiety or combination use exist.\\n\\n## Mechanisms (Mechanistic Tier)\\n\\nPT-141 acts centrally via melanocortin receptors to modulate arousal signaling independent of vascular pathways.\\n\\nSelank influences GABA-A receptor subunit expression and shows non-benzodiazepine anxiolytic activity in preclinical and limited human transcriptomic studies.\\n\\n## Combination and SSRI Context\\n\\nNo human data, preclinical studies, or user reports in indexed sources address the PT-141 + Selank combination or its use specifically for SSRI-induced sexual dysfunction and anxiety. Any application remains speculative.\\n\\n## Evidence Summary\\n\\n- PT-141: Human (FDA approval and ","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"f9a9e1e7576235583ddf018503e015bf7da23bc7393a348781cd3051c911f81a"},{"ts":"2026-06-29T12:11:05.997Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141-selank-ssri","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f9a9e1e7576235583ddf018503e015bf7da23bc7393a348781cd3051c911f81a","hash":"1a90dd8963f2928804c6cd89195ba5e76ecfc62f9199aafceac79e2b1a575eb3"},{"ts":"2026-06-29T12:11:26.573Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141-selank-ssri","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1a90dd8963f2928804c6cd89195ba5e76ecfc62f9199aafceac79e2b1a575eb3","hash":"0d1af692666a3c858dc85b81dae890db8d0fa27c4ad078186de5dff73b1ec7fd"},{"ts":"2026-06-29T12:46:46.727Z","model":"system/audit-repair","action":"repair","prompt":"","input":"pt-141-selank-ssri","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0d1af692666a3c858dc85b81dae890db8d0fa27c4ad078186de5dff73b1ec7fd","hash":"c30737458d85d01a57bb91dda716e919ec77468d4b3981b772f0f3a97b783909"},{"ts":"2026-06-29T12:46:47.304Z","model":"system/audit-repair","action":"claim","prompt":"","input":"pt-141-selank-ssri c13","response":"PT-141 + Selank for SSRI Users: Evidence Review is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c30737458d85d01a57bb91dda716e919ec77468d4b3981b772f0f3a97b783909","hash":"0b6b817ff365cc08b84188d19c975d312ea8b0fec7f9d1235c1b8899cf93a92e"},{"ts":"2026-06-29T12:46:47.363Z","model":"system/audit-repair","action":"claim","prompt":"","input":"pt-141-selank-ssri c14","response":"Per this ledger on PT-141 + Selank for SSRI Users: Evidence Review: 6 scientific and 5 anecdotal sources are catalogued; 3 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0b6b817ff365cc08b84188d19c975d312ea8b0fec7f9d1235c1b8899cf93a92e","hash":"38391463d61364c2306a3f6023045700f5513b211defd64f5b5fff05f2a702a9"},{"ts":"2026-06-29T12:46:47.444Z","model":"system/audit-repair","action":"claim","prompt":"","input":"pt-141-selank-ssri c15","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"38391463d61364c2306a3f6023045700f5513b211defd64f5b5fff05f2a702a9","hash":"ed02bebb30bc12c8ff14081463cb00eb583a00a5328b38f30ce4743e7fd1bedc"},{"ts":"2026-06-29T12:46:47.477Z","model":"system/audit-repair","action":"claim","prompt":"","input":"pt-141-selank-ssri c16","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ed02bebb30bc12c8ff14081463cb00eb583a00a5328b38f30ce4743e7fd1bedc","hash":"1ccf78246dd19ce2772b64b7bf52174f8e35f65b9b03c8c5b448ecb6c1f1af97"},{"ts":"2026-06-29T12:46:47.550Z","model":"system/audit-repair","action":"claim","prompt":"","input":"pt-141-selank-ssri c17","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1ccf78246dd19ce2772b64b7bf52174f8e35f65b9b03c8c5b448ecb6c1f1af97","hash":"b1b57b80b2e5f34d46126d6c6d2801ce623cd9f4e5e1a6b96acc9ed281302e1b"},{"ts":"2026-06-29T12:46:48.310Z","model":"system/audit-repair","action":"repair","prompt":"","input":"pt-141-selank-ssri","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b1b57b80b2e5f34d46126d6c6d2801ce623cd9f4e5e1a6b96acc9ed281302e1b","hash":"cb05af9db6257b2e4cdfbcdb54246c9e222566f79e60f0da20ab8eacb4866ad0"},{"ts":"2026-06-29T13:25:04.810Z","model":"system/audit-repair","action":"repair","prompt":"","input":"pt-141-selank-ssri","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"cb05af9db6257b2e4cdfbcdb54246c9e222566f79e60f0da20ab8eacb4866ad0","hash":"e7bcc4e75591acdfb11c419d4f643e265697c93b20217326eaa60a73a6568aa6"},{"ts":"2026-06-29T13:25:05.973Z","model":"system/audit-repair","action":"repair","prompt":"","input":"pt-141-selank-ssri","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e7bcc4e75591acdfb11c419d4f643e265697c93b20217326eaa60a73a6568aa6","hash":"a0806a36b128be5bcb1ff60de4c1b200eb37024cd73294f054ab54c3d325a276"},{"ts":"2026-06-29T13:55:48.022Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"pt-141-selank-ssri","response":"I am adding explicit gaps in knowledge (what_is_unknown) and identifying who claims what from anecdotes that are missing in the current ledger, as instructed. I am not Grok because I am contributing by adding missing claims rather than challenging existing ones.","tokens_in":3195,"tokens_out":323,"cost":0,"prev":"a0806a36b128be5bcb1ff60de4c1b200eb37024cd73294f054ab54c3d325a276","hash":"ac396382a518103a2ffaf322c9d291f8305ff655a093dea64e97b00d164b2151"},{"ts":"2026-06-29T20:06:02.579Z","model":"repair","action":"repair","prompt":"","input":"pt-141-selank-ssri","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":11}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ac396382a518103a2ffaf322c9d291f8305ff655a093dea64e97b00d164b2151","hash":"8a2b90eb1cb95e9d07882ffee7e5e4722d7adbb9dce67ecb6bdc9e34b4c552b3"},{"ts":"2026-06-29T21:17:02.152Z","model":"fill-slots","action":"claim","prompt":"","input":"pt-141-selank-ssri c20","response":"PT-141 + Selank for SSRI Users: Evidence Review is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8a2b90eb1cb95e9d07882ffee7e5e4722d7adbb9dce67ecb6bdc9e34b4c552b3","hash":"401079f207925378bdd6e04b61c9eefa03f28a84247901716c820549af425e83"},{"ts":"2026-06-29T21:17:03.565Z","model":"fill-slots","action":"claim","prompt":"","input":"pt-141-selank-ssri c21","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"401079f207925378bdd6e04b61c9eefa03f28a84247901716c820549af425e83","hash":"f974caffb2f7403f4583ec10e739c7f69f4404dab40933cd1f39445e773c7f5e"},{"ts":"2026-07-17T02:41:10.196Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-selank-ssri","response":"17 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f974caffb2f7403f4583ec10e739c7f69f4404dab40933cd1f39445e773c7f5e","hash":"b995ed4fc3b5f9876fe0daea27f285aa1d4f77d5d69903ff447ff92278900afb"}]}